Your browser doesn't support javascript.
loading
Complement and contact system activation in acute congestive heart failure patients.
Suffritti, C; Tobaldini, E; Schiavon, R; Strada, S; Maggioni, L; Mehta, S; Sandrone, G; Toschi-Dias, E; Cicardi, M; Montano, N.
Affiliation
  • Suffritti C; Departments of Biomedical and Clinical Sciences 'L. Sacco', University of Milan, Milan, Italy.
  • Tobaldini E; Department of Internal Medicine, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy.
  • Schiavon R; Department of Clinical Sciences and Community of Health, University of Milan, Milan, Italy.
  • Strada S; Internal Medicine, L. Sacco Hospital, University of Milan, Milan, Italy.
  • Maggioni L; Internal Medicine, L. Sacco Hospital, University of Milan, Milan, Italy.
  • Mehta S; Departments of Biomedical and Clinical Sciences 'L. Sacco', University of Milan, Milan, Italy.
  • Sandrone G; Biomedical Research and Environmental Sciences, JES Tech, Houston, TX, USA.
  • Toschi-Dias E; Internal Medicine, L. Sacco Hospital, University of Milan, Milan, Italy.
  • Cicardi M; Heart Institute (InCor), University of Sao Paulo Medical School, Sao Paulo, Brazil.
  • Montano N; Departments of Biomedical and Clinical Sciences 'L. Sacco', University of Milan, Milan, Italy.
Clin Exp Immunol ; 190(2): 251-257, 2017 11.
Article in En | MEDLINE | ID: mdl-28707730
ABSTRACT
Recent experimental data indicate a pathogenic role of complement activation in congestive heart failure (CHF). The aim of this study was to evaluate contact and complement systems activation in patients hospitalized for an acute episode of CHF. Forty-two of 80 consecutive patients admitted at our hospital with confirmed diagnosis of acute CHF were enrolled. They underwent blood sampling within 24 h from admission (T0) and at clinical stability (T1). Patients were stratified for ejection fraction (EF) based on echocardiographic test. We measured plasma levels of C3, C4, sC5b-9 and cleaved high molecular weight kininogen (contact activation marker). At T1, C3 levels increased significantly compared to T0 (97 ± 2 versus 104 ± 3% of total pooled plasma, P < 0·01). Classifying patients according to EF, only patients with preserved EF presented a significant increase of C3 from T0 to T1 (99 ± 3 versus 108 ± 4%, P = 0·03). When the sample was stratified according to clinical outcome, C3 (98 ± 3 versus 104 ± 4%, P = 0·03) and sC5b-9 levels (204 ± 10 versus 230 ± 11 ng/ml, P = 0·03) were increased in patients who had positive outcome after hospitalization. CHF patients with preserved EF and positive outcome after hospitalization showed higher levels of sC5b-9 in the T1 period compared with T0 (211 ± 14 versus 243 ± 14 ng/ml, P = 0·04). Our results suggest that the complement system reacts differently if CHF occurs with preserved or reduced EF. This finding is interesting if we consider the difference in epidemiology, pathogenesis and possible therapeutic approaches of these two clinical entities.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Complement Activation / Heart Failure Type of study: Diagnostic_studies Limits: Aged / Aged80 / Female / Humans / Male Language: En Journal: Clin Exp Immunol Year: 2017 Document type: Article Affiliation country: Italia

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Complement Activation / Heart Failure Type of study: Diagnostic_studies Limits: Aged / Aged80 / Female / Humans / Male Language: En Journal: Clin Exp Immunol Year: 2017 Document type: Article Affiliation country: Italia